DeKeyser Joshua G, Stagliano Michael C, Auerbach Scott S, Prabhu K Sandeep, Jones A Daniel, Omiecinski Curtis J
Center for Molecular Toxicology and Carcinogenesis, Department of Veterinary and Biomedical Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
Mol Pharmacol. 2009 May;75(5):1005-13. doi: 10.1124/mol.108.053702. Epub 2009 Feb 11.
The human constitutive androstane receptor (CAR, CAR1) regulates the expression of genes involved in xenobiotic metabolism in the liver. The CAR gene uses multiple alternative splicing events during pre-mRNA processing, thereby enhancing the CAR transcriptome. Previous reports have identified two prominent human CAR variants, CAR2 and CAR3, that possess four- and five-amino acid insertions in their ligand binding domains, respectively. Unlike the constitutively active reference form of the receptor, we now demonstrate that CAR2 is a ligand-activated receptor and comprises approximately 30% of the reference transcript level in human liver tissues in human hepatocytes. Furthermore, we identify the common plasticizer, di(2-ethylhexyl) phthalate (DEHP), as a highly potent and uniquely selective agonist of CAR2. Results from reporter transactivation and mammalian two-hybrid assays reveal that DEHP activates CAR2 at low nanomolar concentrations, results further supported by analysis of CAR target gene expression in primary human hepatocytes. In addition, comparative genomic analyses show that the typical mouse, rat, and marmoset models of DEHP toxicity cannot accurately profile potential human toxicity because of these species' inability to generate a CAR2-like transcript. The discovery that CAR2 is an ultimate human DEHP receptor identifies a novel pathway modulating human DEHP toxicity with potential clinical implications for a subset of patients undergoing critical care medical interventions.
人类组成型雄甾烷受体(CAR,CAR1)调节肝脏中参与异生物质代谢的基因表达。CAR基因在mRNA前体加工过程中会发生多种可变剪接事件,从而丰富了CAR转录组。先前的报道已鉴定出两种主要的人类CAR变体,即CAR2和CAR3,它们在配体结合域中分别具有四个和五个氨基酸的插入。与组成型活性受体参考形式不同,我们现在证明CAR2是一种配体激活受体,在人类肝细胞的肝组织中约占参考转录水平的30%。此外,我们确定常见增塑剂邻苯二甲酸二(2-乙基己基)酯(DEHP)是CAR2的一种高效且独特的选择性激动剂。报告基因反式激活和哺乳动物双杂交试验结果表明,DEHP在低纳摩尔浓度下即可激活CAR2,原代人肝细胞中CAR靶基因表达分析进一步支持了这一结果。此外,比较基因组分析表明,由于典型的小鼠、大鼠和狨猴DEHP毒性模型无法产生类似CAR2的转录本,因此不能准确描述潜在的人类毒性。CAR2是人类DEHP终极受体这一发现,确定了一条调节人类DEHP毒性的新途径,对接受重症监护医疗干预的部分患者具有潜在临床意义。